Silence Therapeutics, PLC enters into a Settlement and License Agreement with Alnylam Pharmaceuticals

Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces today a Settlement and License Agreement with Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY). Alnylam will license patents from Silence and will pay Silence a tiered royalty on net sales of ONPATTRO™in the EU only ranging from 0.33 percent to 1.0 percent through 2023. All legal proceedings in all jurisdictions between the companies are resolved under the settlement. 

David Horn Solomon, Chief Executive Officer of Silence Therapeutics, commented:

“We are excited for the potential of ONPATTRO™ to treat patients with hereditary ATTR amyloidosis polyneuropathyas the first RNAi medicine and are looking forward to following Alnylam’s achievements. At Silence Therapeutics we now look forward to focusing on advancing a pipeline of competitive and differentiated medicines that will benefit patients and caregivers.”

About Silence Therapeutics plc

SilenceTherapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using its enabling delivery systems, it has achieved an additional level of specificity by delivering its therapeutic RNA molecules exclusively to target cells. Silence’s proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.  For more information, please visit: https://www.silence-therapeutics.com/